SCCAMP V1.0
Research type
Research Study
Full title
Scottish COVID CAncer iMmunity Prevalence (SCCAMP) study
IRAS ID
286449
Contact name
Peter Hall
Contact email
Sponsor organisation
University of Edinburgh
Clinicaltrials.gov Identifier
na, na
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
The COVID-19 pandemic has had a significant impact on the care of cancer patients. This is partly due to concerns that cancer patients may be more vulnerable to severe infection but is also due to disruption to cancer services. We do not currently know how many cancer patients have been exposed to, and infected by, COVID-19. We are uncertain if infection leads to long term immunity, or if it is possible to be re-infected for a second time.
Cancer patients tend to have a reduced immune system due to their disease or their treatment. This means that we need to conduct specific studies of COVID-19 immunity in cancer patients. We need to understand which treatments affect immunity and what other factors influence this.
The SCCAMP study will test for COVID-19 antibody levels in patients having cancer treatment. It aims to establish how many patients have evidence of prior COVID-19 infection, how antibody levels change over time and the extent to which antibody levels reflect immunity to severe infection.
The results will be important in understanding the risk posed by COVID-19 to patients on anti-cancer treatment This information will guide patients and doctors who are making choices about treatment options. It will also help guide the planning of cancer services for the duration of the COVID-19 pandemic.
REC name
South East Scotland REC 02
REC reference
20/SS/0109
Date of REC Opinion
17 Nov 2020
REC opinion
Further Information Favourable Opinion